KingMed Diagnostics

What KingMed Diagnostics does

KingMed Diagnostics (金域医学, SSE: 603882) is China's largest independent third-party medical testing and pathology diagnostic services provider, founded in 1994 and headquartered in Guangzhou. The company operates a nationwide service network spanning all 31 Chinese provinces plus Hong Kong, comprising 700+ co-built regional testing and pathology diagnosis centers and serving 23,000+ medical institutions ranging from tertiary hospitals to township health centers. Its core offering provides access to 4,300+ clinical testing items across multiple technology platforms including genomics, mass spectrometry, pathology, immunology, and molecular diagnostics, supported by wholly-owned subsidiaries for cold chain logistics (Kingda Logistics), forensic identification, health checkups, sanitation testing (Jinzhi Testing), and clinical trials support.

The company's revenue model is anchored in B2B clinical testing services priced on a quote/transaction basis to healthcare institutions, with diversified supplementary streams including health management subscriptions, clinical trials services, cold chain logistics, and data product monetization through 38+ listings on Beijing, Shanghai, and Guangzhou data exchanges. Distribution runs through a direct enterprise sales model with regional offices and field sales teams targeting hospital administrators and clinical departments across all healthcare system levels.

KingMed has built a vertically integrated AI stack atop its 30PB+ proprietary medical testing dataset, anchored by the Yujian Yuyan LLM (industry-first medical testing vertical LLM, August 2024) and 60+ intelligent agents under the Small Domain Medical (小域医) series. Strategic technology partnerships include Tencent (DeepGEM pathology-genomics multimodal model), Huawei Cloud (Yujian Yuyan All-in-One Machine), and China Unicom Smart Medical (AI Doctor system), with co-development of clinical AI alongside top academic hospitals including Guangzhou Medical University First Affiliated Hospital, Peking University Third Hospital, and Zhongshan Third Hospital. Notable differentiators include selection as the only medical institution in the National Data Bureau's first batch of trusted data space innovation pilots, DCMM Level 3 certification (first in the medical testing sector), and National Intellectual Property Demonstration Enterprise status (2019).

Name

KingMed Diagnostics

Legal name

Guangzhou Kingmed Medical Laboratory Group Co., Ltd. (广州金域医学检验集团股份有限公司)

Website

https://kingmed.com.cn

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

KingMed Diagnostics is China's largest independent third-party medical testing and pathology diagnostic services provider, serving 23,000+ medical institutions across all 31 provinces with 4,300+ testing items, anchored by a proprietary AI platform built on 30PB of medical testing data.

Ownership category

akta.pro rank

Product category

Clinical Laboratory and Pathology Diagnostic Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAHAAAE

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics)

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

SECONDARYHLAAALAI

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLACANAD

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software

Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

SECONDARYHLAHAAAN

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

• Clinical laboratory services
• Medical diagnostic testing
• Pathology diagnostic services
• Third-party medical testing
• Clinical genomic testing

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Testing and Pathology Diagnostic Services: Core revenue stream from providing medical testing services to hospitals and healthcare institutions. Services include clinical diagnosis information services, disease specialist alliances, and comprehensive laboratory solutions for medical institutions at all levels.
2. New Health Management Services: Integrated health management solutions for public health, research, insurance and other industries, providing comprehensive health management services.
3. Data Product Sales: 21+ data products listed on Beijing, Shanghai, and Guangzhou data exchanges covering infection, tumor, neurology, and genetics domains. Revenue generated from selling data analytics reports and algorithm models to pharma companies, CDC, and insurance firms.
4. Cold Chain Logistics (金域达物流): Professional medical cold chain logistics services supporting sample transportation for testing operations.
5. Clinical Trials Services: Clinical trial support services for pharmaceutical companies and medical institutions.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

KingMed Diagnostics is China's leading independent third-party medical laboratory and pathology diagnostics provider, offering over 4,300 clinical testing and pathology diagnostic items to more than 23,000 medical institutions across all 31 provinces and Hong Kong. The company provides clinical diagnosis information services, disease specialist alliances, laboratory overall solutions (from design to operation), new health management services, and a growing portfolio of AI-powered diagnostic products including the Yujian Yuyan Medical LLM, Small Domain Medical AI agents, and AI-driven smart laboratory workstations.

Product overview

KingMed Diagnostics operates as a comprehensive medical examination and pathology diagnostics platform with a 'platform + module' architecture. The core offering includes clinical diagnosis information services integrating multiple technology platforms (genomics, mass spectrometry, pathology, immunology) providing over 4,300 testing items. The company has developed an AI ecosystem anchored by the '域见医言大模型' (Yujian Yuyan Medical LLM) - the industry's first medical examination vertical large language model - and its associated '小域医' (Small Domain Medical) AI agent series with 60+ intelligent agents. Supporting infrastructure includes the AI开放创新平台 (AI Open Innovation Platform) for external AI development, the 医检可信数据空间 (Trusted Medical Data Space) for secure data exchange, and 金域云检KMC customer service platform. The company also offers integrated solutions including laboratory design and management, health management services, cold chain logistics, forensic identification, sanitation testing, and health examinations. Services are delivered through a nationwide service network covering 31 provinces and serving 23,000+ medical institutions annually.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Diagnosis Information Services (临床诊断信息服务) Comprehensive clinical diagnosis information services integrating multiple technology platforms (genomics, mass spectrometry, pathology, immunology) and testing methods to help clinical doctors make accurate diagnoses across oncology, genetics, infectious diseases, and rare diseases.
• Yujian Yuyan Medical LLM (域见医言大模型) Industry's first medical examination vertical domain large language model providing intelligent medical services including report interpretation, diagnosis assistance, and health management by leveraging 30+ years of medical examination data and knowledge.
• Small Domain Medical AI Agent Series (小域医) AI agent application series providing intelligent services including test project recommendations, report interpretation, disease diagnosis assistance, medication support, and health checkup report generation for doctors and patients.
• AI Open Innovation Platform (AI开放创新平台) AI development and deployment platform enabling external developers and partners to build medical AI applications on KingMed's infrastructure and medical data capabilities.
• Trusted Medical Examination Data Space (医检可信数据空间) Trusted medical examination data exchange platform facilitating secure circulation and collaboration of medical data. Named as national first batch trusted data space innovation pilot by the National Data Bureau.
• Smart Laboratory Solutions (智慧实验室)
• KingMed Cloud Check KMC (金域云检KMC)
• Overall Laboratory Solutions (整体解决方案)
• New Health Management Services (新型健康管理)
• Cold Chain Logistics (冷链物流)
• Sanitation Testing (卫生检验)
• Forensic Identification (司法鉴定)
• Health Examination (健康体检)
• Clinical Testing Services (临床检测)
• Disease Specialist Alliances (疾病专科联盟)
• Data Element Services (数据要素×)
• DeepGEM Pathological-Genomic Multimodal Model AI model jointly developed with Tencent that predicts lung cancer gene mutations from routine histopathological images with 78%-99% accuracy in 1 minute, potentially reducing gene detection costs by over 80%.
• AI Doctor System (Zhongshan Third Hospital AI Doctor) AI doctor platform jointly developed with Zhongshan Third Hospital and China Unicom Smart Medical, covering the full symptom-exam-diagnosis-treatment-followup chain for clinical decision support.

Quantifiable outcome

• AI-assisted cervical cancer screening efficiency improved 4x while maintaining quality standards
• +4 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability11 records

Feature6 records

Partnerships

24 partnerships are on record, tiered major, core and minor.

• Shanghai Tongkang Hospital (上海同康医院)majorStrategic or Co-development Partner · 11 June 2026Strategic cooperation framework agreement to build integrated smart medical service system, focusing on elderly care, tumor, infection, and neuroimmune diseases.
• Peking University Third Hospital (北京大学第三医院)coreStrategic or Co-development Partner · 10 June 2026Jointly established Beijing Key Laboratory for Neurological Rare Diseases Innovation Diagnosis and Transformation. Research focuses on ALS, CMT and other neurological rare diseases.
• Humana Healthcare (和睦家医疗)coreStrategic or Co-development Partner · 8 June 2026Strategic cooperation in International Oncology Center, high-end health management, and brain health. Focus on precision testing services and clinical application scenarios.
• Guangzhou Medical Health AI Industry Alliance (广州医疗健康人工智能产业联盟)majorStrategic or Co-development Partner · 8 June 2026Co-founded alliance with Guangzhou National Laboratory, universities, research hospitals, and tech companies to advance medical AI industry development in Guangzhou.
• Henan University of Traditional Chinese Medicine (河南中医药大学)majorStrategic or Co-development Partner · 26 May 2026Joint establishment of provincial graduate training workstation with Zhengzhou KingMed. Focus on digital medical testing talent cultivation and AI-enabled testing education.
• World Data Organization (WDO)majorOthers · 30 March 2026First member from medical testing industry. WDO aims to bridge data gaps, unlock data value, and prosper digital economy across 40+ countries.
• China Kidney Pathology Collaboration Network (中国肾脏病理协作网)majorStrategic or Co-development Partner · 21 March 2026Core support unit for collaboration network initiated by Fudan University Zhongshan Hospital. Covers nearly 30 provinces with focus on standardizing kidney pathology diagnosis.
• Gilead Sciences (吉利德科学)majorGTM or Marketing Partner · 18 March 2026Joint hepatitis C free screening campaign covering 25 provinces and nearly 200 medical institutions, donating 10,000+ screening tests.
• Guangzhou Women and Children's Medical Center (广妇儿)coreStrategic or Co-development Partner · 1 March 2026Co-founded Birth Defect Prevention and Control Specialty Alliance. 10 provinces, nearly 60 medical institutions, 60,000+ tests performed.
• Nanjing Vazyme (南京诺唯赞)majorStrategic or Co-development Partner · 28 January 2026Strategic cooperation in nervous system disease detection. Focus on AD biomarker detection technology R&D, clinical verification, and market promotion. Build 'technology R&D-clinical verification-market promotion' closed loop.
• Guangxi Medical University (广西医科大学)majorStrategic or Co-development Partner · 21 January 2026Strategic cooperation for digital medical and health ecosystem. Jointly build multimodal specialist disease diagnosis models and intelligent agents, establish 'R&D-verification-transformation' closed loop.
• Fengkai County Government (封开县人民政府)majorStrategic or Co-development Partner · 14 January 2026Deployment of Guangdong Province's first county-level AI-assisted diagnosis platform covering 19 county and township hospitals, serving 500,000 residents.
• Zhongshan Third Hospital (中山大学附属第三医院)coreStrategic or Co-development Partner · 9 January 2026Joint release of AI Doctor system and establishment of Medical Data Intelligence Joint Laboratory. Hospital provides clinical expertise and de-identified diagnosis data for training.
• China Unicom Smart Medical (联通数智医疗)majorTechnology or Integration · 9 January 2026Joint development of AI Doctor system. Provides digital infrastructure, computing power, and system integration capabilities.
• Henan Allergy Disease Collaboration Network (河南省过敏性疾病精准诊疗与临床研究协作网)minorStrategic or Co-development Partner · 27 December 2025Joined as technical support unit providing precision allergy testing services. Network covers 13 medical institutions.
• Guilin Medical University (桂林医科大学)majorStrategic or Co-development Partner · 6 December 2025Joint establishment of Guangxi multimodal biomarker and precision diagnosis key laboratory with Guangxi KingMed and Guilin Youlitu. Develop multi-modal biomarker systems for tumor, genetic rare disease, and cross-border infectious disease.
• Yunnan Allergy Diagnosis and Treatment Alliance (云南省变态反应诊治联盟)minorStrategic or Co-development Partner · 6 December 2025Joined as technical cooperation unit providing standardized allergy disease testing services. Alliance covers 18 hospitals.
• China Prion Disease Alliance (中国朊蛋白病联盟)minorStrategic or Co-development Partner · 19 October 2025Joined as standardized public testing service platform. Provides standardized nervous system and prion disease testing services using RT-QuIC technology.
• Tencent (腾讯)coreTechnology or Integration · 11 October 2025Joint development of DeepGEM pathological-genetic multimodal model with Guangzhou Medical University First Affiliated Hospital. Tencent provides AI technology including multi-instance learning (MIL) and end-to-end architecture. Model predicts lung cancer gene mutations from routine pathology images with 78%-99% accuracy.
• Guangzhou Medical University First Affiliated Hospital / National Respiratory Medicine Center (广州医科大学附属第一医院/国家呼吸医学中心)coreStrategic or Co-development Partner · 11 October 2025Joint development of DeepGEM model with He Jianxing/Liang Wenhua team. Hospital provides clinical expertise and validation data from 4,260 lung cancer patient samples across 30 provinces.
• Nanpi County People's Hospital (南皮县人民医院)majorStrategic or Co-development Partner · 22 August 2025Co-built regional testing center serving county-township-village three-level coordination network. Connected 70 village clinics with nearly 200 specimens processed.
• Beijing International Big Data Exchange, Shanghai Data Exchange, Guangzhou Data ExchangemajorChannel Partner/ Reseller/ Distributor21+ data products listed on these exchanges for compliant medical data circulation to pharma, insurance, and research institutions.
• Guangzhou Medical University (广州医科大学)coreStrategic or Co-development PartnerCo-founded 金域检验学院 with joint curriculum development. Clinical Chromatography Mass Spectrometry Testing Technology course awarded national first-class undergraduate course; Clinical Genomics Testing textbook won provincial excellent textbook award.
• Huawei (华为)majorTechnology or IntegrationJointly developed four 'DomainSee Large Model All-in-One Machine' products with Huawei Cloud. Deployed cervical cancer cell AI-assisted screening model improving efficiency 4x.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies globally, operating a reference lab network similar in concept to KingMed. While geographically separate, the business model of high-volume routine and specialty testing for healthcare providers is directly analogous.
• Eurofins Scientific: Eurofins is a global leader in bioanalytical testing with clinical diagnostics operations. Comparable to KingMed for its clinical reference laboratory services, bioanalytical testing capabilities, and global footprint in medical testing markets.
• Mindray Medical: Mindray is China's largest medical device and IVD instrumentation company, providing in-vitro diagnostic equipment and reagents. It is comparable to KingMed through its IVD reagent business and laboratory automation solutions sold to Chinese hospitals.
• Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network offering routine, esoteric, and anatomic pathology testing to healthcare providers. Comparable to KingMed as a B2B-focused reference lab with broad test menus and extensive logistics infrastructure.

Direct peers

• Da An Gene (Da An Health): Da An Gene is a major Chinese molecular diagnostics company, particularly strong in infectious disease testing and clinical molecular diagnostics. It is comparable to KingMed in clinical PCR and molecular testing service offerings.
• BGI Genomics: BGI Genomics is a leading Chinese genetic testing and genomics company that overlaps with KingMed in molecular diagnostics, NGS-based testing, and genetic disease screening services. Both serve hospital and clinical customers with advanced genetic testing capabilities.
• DiAn Diagnostics: DiAn Diagnostics is one of China's largest third-party medical laboratory service providers and KingMed's most direct domestic competitor. Both companies operate nationwide lab networks serving hospitals, offer similar testing menus, and compete for the same B2B medical institution clients across China.
• ADICON Laboratories: ADICON is another major Chinese independent clinical laboratory company with comparable geographic coverage and service offerings. It competes directly with KingMed in routine and specialty testing services for hospitals and medical institutions.

Emerging players

• Guardant Health: Guardant Health is a leading precision oncology company using liquid biopsy and genomics for cancer detection. Comparable to KingMed's advanced oncology diagnostics (ctDNA NGS standards leadership) and AI-enabled cancer mutation prediction capabilities.
• Tempus AI: Tempus AI is a technology-enabled precision medicine company applying AI to molecular and clinical data. Comparable to KingMed's data and AI strategy (DomainSee LLM, DeepGEM multimodal model) for clinical decision support and data-driven diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kingmed-diagnostics

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KingMed Diagnostics